期刊
NATURE CLINICAL PRACTICE ONCOLOGY
卷 4, 期 9, 页码 536-550出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ncponc0905
关键词
bevacizumab; breast cancer; hypoxia; receptor tyrosine kinase; inhibitor; VeGF
类别
资金
- Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline
Demonstration of the clinically significant activity of bevacizumab in breast cancer has attracted a great deal of interest. Numerous other antiangiogenic treatments are in clinical development and some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. In this Review, we discuss the potential of various components of the angiogenic pathway as prognostic and predictive factors in breast cancer. In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据